Sierra Wallace, PA
Physician Assistant · Hutchinson, KSNPI 1740835941
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 372 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 372 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$973
- Vanda Pharmaceuticals Inc.$709
- Johnson & Johnson$682
- Alkermes, Inc.$636
- Teva Pharmaceuticals USA, Inc.$630
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$594
- plus $3K from 16 others
What the payments were for
- Food & beverage$6,62798%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $973 |
| Vanda Pharmaceuticals Inc. | 32 | $709 |
| Johnson & Johnson | 40 | $682 |
| Alkermes, Inc. | 34 | $636 |
| Teva Pharmaceuticals USA, Inc. | 30 | $630 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $594 |
| Supernus Pharmaceuticals, Inc. | 25 | $425 |
| Axsome Therapeutics, Inc. | 11 | $368 |
| Otsuka America Pharmaceutical, Inc. | 19 | $361 |
| Neurocrine Biosciences, Inc. | 18 | $330 |
| Lundbeck LLC | 16 | $304 |
| Indivior Inc. | 8 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $139 |
| E.r. Squibb & Sons, L.L.C. | 6 | $139 |
| Corium, LLC | 5 | $84 |
| CSL Behring | 2 | $66 |
| Sanofi | 1 | $43 |
| Biogen | 2 | $42 |
| Eisai Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$6,738 in reported general payments places this provider in the 90th percentile of 1,016 physician assistant providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 24 | $187,175 |
| Abilify MaintenaAripiprazole | 31 | $90,040 |
| VraylarCariprazine Hcl | 58 | $86,749 |
| Invega SustennaPaliperidone Palmitate | 22 | $49,281 |
| RexultiBrexpiprazole | 29 | $42,782 |
| CaplytaLumateperone Tosylate | 14 | $25,630 |
| TrintellixVortioxetine Hydrobromide | 32 | $15,701 |
| Lurasidone Hcl | 59 | $14,665 |
| BelsomraSuvorexant | 13 | $6,799 |
| Aripiprazole | 92 | $5,153 |
| Doxepin Hcl | 40 | $4,840 |
| Hydroxyzine Hcl | 163 | $4,760 |
| Quetiapine Fumarate | 291 | $3,948 |
| Duloxetine Hcl | 266 | $3,320 |
| Atomoxetine Hcl | 32 | $2,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $630 | $187,17524 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $361 | $132,82360 claims |
| AbbVieVraylar | $973 | $86,74958 claims |
| Johnson & JohnsonInvega Sustenna | $682 | $49,28122 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $594 | $25,63014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $139 | $15,70132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in Hutchinson
- Melanie SennHutchinson$9K
- Matthew OsenbaughHutchinson$9K
- Sierra FergusonWichita$25K
- Dylan TimmermannTopeka$19K
- Heather HowellKansas City$16K
- Amy BrettmanShawnee$14K
- Ashton YoungersWichita$14K
- Anthony GunawanLakin$13K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.